Mitogen-activated protein kinase activation by stimulation with thyrotropin-releasing hormone in rat pituitary GH3 cells.
We examined whether mitogen-activated protein (MAP) kinase is activated by thyrotropin-releasing hormone (TRH) in GH3 cells, and whether MAP kinase activation is involved in secretion of prolactin from these cells. Protein kinase inhibitors--such as PD098059, calphostin C, and genistein--and removal of extracellular Ca2+ inhibited MAP kinase activation by TRH. A cAMP analogue activated MAP kinase in these cells. Effects of cAMP on MAP kinase activation were inhibited by PD098059. TRH-induced prolactin secretion was not inhibited by levels of PD098059 sufficient to i activation but was inhibited by wortmannin (1 microM) and KN93. Treatment of GH3 cells with either TRH or cAMP significantly inhibited DNA synthesis and induced morphological changes. The effects stimulated by TRH were reversed by PD098059 treatment, but the same effects stimulated by cAMP were not. Treatment of GH3 cells with TRH for 48 h significantly increased the prolactin content in GH3 cells and decreased growth hormone content. The increase in prolactin was completely abolished by PD098059, but the decrease in growth hormone was not. These results suggest that TRH-induced MAP kinase activation is involved in prolactin synthesis and differentiation of GH3 cells, but not in prolactin secretion.
Kanasaki
H
H
Department of Pharmacology, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan Department of Obstetrics and Gynecology, Shimane Medical University, Izumo 693-8501, Japan.
Fukunaga
K
K
Takahashi
K
K
Miyazaki
K
K
Miyamoto
E
E
D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology; D002118:Calcium / Q000008:administration & dosage; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D019833:Genistein / Q000494:pharmacology; D006728:Hormones / Q000378:metabolism; D009281:Naphthalenes / Q000494:pharmacology; D010911:Pituitary Neoplasms / Q000201:enzymology*; D011388:Prolactin / Q000378:metabolism; D015175:Prolactinoma / Q000201:enzymology*; D051381:Rats; D013449:Sulfonamides / Q000494:pharmacology; D013873:Thionucleotides / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D000077191:Wortmannin; D000096926:Benzenesulfonamides
D000730:Androstadienes; D001596:Benzylamines; D002118:Calcium; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D000242:Cyclic AMP; D004247:DNA; D004791:Enzyme Inhibitors; D005419:Flavonoids; D019833:Genistein; D006728:Hormones; D009281:Naphthalenes; D011388:Prolactin; D013449:Sulfonamides; D013873:Thionucleotides; D013973:Thyrotropin-Releasing Hormone; D000077191:Wortmannin; C072105:KN 93; D000096926:Benzenesulfonamides; C015929:8-((4-chlorophenyl)thio)cyclic-3',5'-AMP; C058819:calphostin C; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one